BioSpace News Archive

Neonode Inc. (NASDAQ: NEON) is pleased to announce that Elix Systems SA has extended its agreement with Neonode and will increase the use of Neonode’s Touch Sensor Modules to enable touch interaction on displays in medical ultrasound systems.

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated April 9, 2021, to its short form base prospectus dated March 31, 2021.

Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.

The commercial success of monoclonal antibodies in major pharmaceutical markets sparked the development of multispecific antibodies.

The Board of Directors of Oncopeptides AB has resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022, to issue and immediately thereafter re-purchase a total of 3,940,607 class C shares.

To address the growing need for simplified, rapid testing for Monkeypox, BioGX, a global provider of easy molecular diagnostic solutions, announced availability of Xfree PCR reagents for Sample-to-Answer Direct Sample PCR on multiple real-time PCR platforms including BioGX’s rapid “pixl” platform.

According to Nova one advisor, the global Cell-based Assays market size is expected to hit around USD 34.8 billion by 2030 from valued at USD 15.95 billion in 2021 and growing at a CAGR of 8.75% from 2022 to 2030

According to Nova one advisor, the global Upstream Bioprocessing market size was valued at USD 10.60 billion in 2021 and is predicted to hit USD 22.9 billion by 2030 with a registered CAGR of 16.4% during the forecast period 2022 to 2030.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:00 PM Eastern Time.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent business highlights.